Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.
Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.
Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.
The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is surrounding what the approach for first line treatment would be for a patient with good performance status, lung adenocarcinoma, metastatic disease and adrenal lesions.
To join the conversation, visit https://cancergrace.org/forum. For a full listing of this Case Based Series please visit https://cancergrace.org/sponsor/case-based-panel-discussions-2019-lung-cancer.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…